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The World Health Organization (WHO) defines adverse drug reaction (ADR) as "A response to a drug, which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function."\[[@ref1]\] It has been demonstrated by a number of studies that drug-induced morbidity and mortality is one of the major health problems in our country.\[[@ref2][@ref3]\] The Pharmacovigilance Programme of India (PvPI) is an initiative to address this issue. Activities under PvPI include collection, reporting, and follow-up of ADRs occurring in patients. The PvPI collate the data received from various Adverse Drug Reaction Monitoring Centers (AMCs) in the country and submit them on regular basis to global database maintained at Uppsala, Sweden. The signals generated from such activities are used to recommend regulatory interventions in the form of banning a drug, labeling revisions besides communicating risks to health-care professionals and the public. The ultimate of PvPI is to identify, characterize, and estimate the extent of the problem associated with drug use in the country.

Cancer is one of the three leading causes of death in the modern world.\[[@ref4]\] It is estimated to cause 12% death annually worldwide.\[[@ref5]\] The incidence of cancer is about 70--90/100,000 persons, and prevalence is estimated approximately 2.5 million in India.\[[@ref5]\] Cancer chemotherapy has improved drastically over a past few decades. Chemotherapy is now employed as a multimodal approach for treatment of different malignancies and has been revolutionized with the discovery of newer drugs for curative treatment for certain fatal malignancies.\[[@ref6]\]

Antineoplastic agents can damage normal cells along with cancerous cell and have narrow therapeutic index.\[[@ref7]\] Patients on chemotherapy are vulnerable to ADRs as they receive multiple drugs as a part of the anticancer regimen. Complications secondary to chemotherapy include an increase in morbidity and mortality.\[[@ref8]\] The patients after undergoing chemotherapy have a general sense of low feeling, have restricted mobility due to the aggravated physical discomfort, spend more time on bed, have low sexual desire, reduce interaction with society, and have less working capabilities.\[[@ref9]\] In other words, the application of chemotherapy regimens and its courses increase the unwanted toxic side effects which gradually aggravate the quality of life of the patients as mentioned in Ma *et al*.\[[@ref10]\] Thus, an active drug surveillance system is needed to capture drug-related risk information in cancer patients. The aim of the study was to determine the nature and severity of ADRs in cancer patients based on ADRs received from the department of radiation oncology. All these ADRs were reported to AMC established under PvPI at All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.

Materials and Methods {#sec1-2}
=====================

AIIMS, Jodhpur, is an Institute of National Importance established under Pradhan Mantri Swasthya Suraksha Yojana and still is in establishing stage. However, AMC was established since the inception of outpatient services. The ADRs received from March 2015 to August 2017 were compiled and discussed here. It was a retrospective cohort study, and the data were extracted from the filled ADR forms received by AMC. The same ADR information was also entered in "VigiFlow" software for reporting to the National Coordinating Center (NCC). The collected data were later summarized and were used to determine the nature and severity of ADRs. AMC is actively involved not only in collecting ADR data from the hospital but also spreading awareness about the need and importance of pharmacovigilance. This is achieved by sending weekly reminder e-mails, regular sharing of drug safety alerts, newsletter, other advertising materials, running animations on television (TV) panels in inpatient department (IPD) and outpatient department (OPD) areas, prescription sheets including patient-centered message emphasizing the need for reporting ADR, distributing pamphlets, and sensitization sessions to health-care professionals (HCPs) and paramedical staff. The ADR (version 1.2) form is a simplified version of the Central Drugs Standard Control Organization\[[@ref11]\] adopted by the center to facilitate reporting by the HCPs. The HCPs either fill the ADR forms themselves or inform the AMC telephonically. In addition, the Patient Safety Pharmacovigilance Associate makes a regular visit to OPD and IPD. The collected individual case safety report was analyzed for patient demography, causality, severity, and preventability of the event. All ADRs were submitted to NCC through "VigiFlow" software. ADRs were classified on the basis of Anatomical and Therapeutic Classification System (1999).\[[@ref12]\] Causality assessment of ADRs was done by causality assessment scale proposed by the WHO Collaborating Centre for International Drug Monitoring--the Uppsala Monitoring Centre\[[@ref13]\] which classifies suspected ADRs as certain, probable, possible, unlikely, conditional/unclassified, and unassessable/unclassifiable. The severity of the ADRs was assessed by Modified Hartwig and Siegel Scale\[[@ref14]\] which gives an impression of the severity of ADRs and tags it as mild, moderate, or severe. Preventability of the ADRs was assessed by Modified Schumock and Thornton Scale.\[[@ref15]\] This scale of preventability classifies ADRs as definitely preventable, probably preventable, and not preventable. Descriptive statistic was used to summarize and analyze the available data on nature and the frequency of various ADRs.
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=======

A total of 191 chemotherapy-induced ADRs from 164 patients were received by AMC until August 2017. The majority of ADRs occurred in the age group of 19--65 years (*n* = 126, 77%) with a female preponderance (*n* = 88, 54%) \[[Figure 1](#F1){ref-type="fig"}\]. In some patients, more than one ADR was observed. Monotherapy constitutes only 50 (26%) drug reactions, while 141 (74%) reactions were from those who received these drugs as a part of a multidrug regimen. The various indications for the use of chemotherapy were tumors of the breast, lung, ovary, oral cavity, lymphoma, and other malignancies \[[Figure 2](#F2){ref-type="fig"}\]. The observations revealed that skin as an organ was involved in almost half of the total ADRs reported followed by hematological (*n* = 43; 23%), gastrointestinal (*n* = 33; 17%), renal, nervous, and other systems (*n* = 25; 13%) \[[Figure 3](#F3){ref-type="fig"}\]. Alopecia, hyperpigmentation of the skin and nail, thrombophlebitis, bone marrow depression, neuropathy, and vomiting were among the common reactions observed \[[Figure 4](#F4){ref-type="fig"}\]. Docetaxel, carboplatin, cisplatin, and cyclophosphamide were the most common drugs involved in ADRs in the study population \[[Figure 5](#F5){ref-type="fig"}\]. Most reactions were mild (54.45%) in nature and the remainder being moderate (44.50%) and severe (1.04%) as assessed by Modified Hartwig and Siegel Scale. There were a total of 45 (including one death) serious adverse events that required hospitalization or caused prolongation of existing hospitalization due to either intractable vomiting, electrolyte imbalance, blood transfusion secondary to anemia, or febrile neutropenia. Assessment by Modified Schumock and Thornton Scale of ADR preventability showed that most of the ADRs belonged to the category of "preventable" (*n* = 174). The majority of the reactions were related "possible" (more than two-third) to drugs as determined by causality assessment \[[Figure 6](#F6){ref-type="fig"}\].
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ADRs due to cancer chemotherapy are quite challenging as it impacts the quality of life of patients and also to the providers who manage such cases.\[[@ref16]\] Chemotherapy-related ADRs increase mortality rate as well as escalate the cost of the therapy.\[[@ref17]\] In India, the scenario is worse as compared to developed countries as only 1% of global data of ADRs due to cancer chemotherapy is reported in India.\[[@ref18][@ref19]\] In our country, due to the low ratio of doctor to patient, most of the events are not reported citing many reasons, i.e., lack of time, low motivation, ignorance, and lethargy. In spite of having trained medical professional in our country, sometimes doctors are hesitant to report because they fear litigation and think that ADR reporting might go against them. Ignorance on the part of the HCPs regarding how to report and no awareness about onco-pharmacovigilance could have contributed to underreporting.\[[@ref20][@ref21]\]

In our study, we found that majority of the ADRs occurred in females\[[@ref22]\] and increased incidence in female patients might be due to hormonal changes occurring during different stages of life that might cause an alteration in the pharmacokinetic profile of the drugs.\[[@ref23]\] Majority of the ADRs occurred in the age group of 19--65 years, which is similar to Astolfi *et al*.\[[@ref24]\] Our findings also showed that most of the ADRs (29.8%) were seen in the age group of 51--60 years as most patients belonged to this age group which is consistent with results of other studies.\[[@ref25][@ref26]\] The metabolizing capacity and the excretory functions are generally diminished as a person ages and there are also pharmacokinetic and pharmacodynamic alterations of drugs in the body and thus increasing the chances of ADRs.\[[@ref27]\]

In our study, most common cancers that had been treated in our setup were breast cancer (*n* = 39; 23.07%) followed by ovarian (*n* = 26; 15.38%), bronchogenic (*n* = 21; 12.42%), and oral cavity cancer (*n* = 16; 9.46%) very similar to reported earlier.\[[@ref25]\] As a whole, Indian data on cancer indicate that the most common cancer among males is oropharyngeal and in females is cervical.\[[@ref28]\] The variation in type that we have observed \[[Figure 2](#F2){ref-type="fig"}\] could be due to the geographical location, dietary habits, and lifestyle.\[[@ref29]\] However, this needs to be further explored in a different study.

ADRs occurring only due to chemotherapy were taken into consideration. The most common drugs causing ADRs were docetaxel (14.2%), carboplatin (11.9%), cisplatin (11.5%), paclitaxel (9.2%), and cyclophosphamide (8.8%). Results of the present analysis are in accordance with reports from a similar study.\[[@ref26]\] In our study, microtubule-damaging drugs account for most of the ADRs as they were most prescribed in a proportionately higher ratio of females which was similar to Astolfi *et al*.\[[@ref24]\]

Among the reported ADRs, common ones were alopecia (17.27%), hyperpigmentation of the skin and nail (14.65%), thrombophlebitis (9.42%), bone marrow depression (8.37%), vomiting (8.376%), and diarrhea (4.71%). The findings were quite similar to a study by Saini *et al*.\[[@ref1]\] Other ADRs experienced by the patients were nausea, burning micturition, constipation, skin rash, and others. Our study is in contrast to studies carried out by Mallik *et al*. which had neutropenia as the most common ADR, while Lau *et al*. reported constipation to be the most common ADR.\[[@ref30][@ref31]\] In our opinion, this difference could be due to either more frequent use of drugs that have bone marrow suppressing effects in one study or overuse of opioid to control intractable pain in many malignancies in another.

In this study, only ADRs were taken into account which occurs due to chemotherapy. Our study has assessed three different parameters of an ADR, namely the causality, severity, and preventability due to the different management plans adopted on the basis of the stage of cancer, cost of the management, and patient-related factors, thus providing basic information regarding the safety profile of anticancer drugs. The WHO causality assessment scale indicated that 70% of the reactions were "possible," which is similar to another onco-pharmacovigilance study.\[[@ref32]\] As anticancer regimens usually include multiple drugs and the explanation, we propose that the other drugs in the regimen might contribute to the reaction observed. Furthermore, it cannot be completely ruled out that sign and symptoms of the disease may sometimes simulate as an ADR in these terminally ill patients. Moreover, information with regard to drug withdrawal secondary to the adverse reaction lack in the majority as ADRs are quite common with such drugs and withdrawal is usually rare in such cases. On the severity scale, most of the reactions were of mild grades which do not warrant stopping or changing of the drug. Preventability scales showed that majority of the ADRs were preventable.

An important limitation of the study is that the re-challenge test was not done in any case due to medical and ethical issues that are the reason behind labeling only two reactions as being "certain." As it was a retrospective study, there are chances of underreporting and incomplete documentation of ADRs data, particularly from initial few reports. We expect that in the near future, the reporting of ADRs will further improve subsequent to the increase in faculty strength of the department.

Conclusion {#sec1-5}
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We may conclude that an effective monitoring and reporting system (onco-pharmacovigilance) will be the most effective tool for better management of chemotherapy-related ADRs. Practices such as an early detection, timely intervention, avoiding agents with overlapping toxicity, or changing the offending agent and substituting it with an alternative agent are few suggestions. Onco-pharmacovigilance will increase the bulk of data on frequency, severity, outcome, etc., associated with anticancer drug use, particularly in the Indian population. We suppose that this will definitely help envisage strategy to prevent or deal with them more effectively. Medical, radio, and surgical oncologists, clinical pharmacologists, and other health-care providers involved in the care of cancer patients must all be involved in the onco-pharmacovigilance program to enhance the quality of data generated by exchanging and updating each other with constructive information. In addition, they should also ensure effective communication and education concerning the appropriate use of drugs in cancer patients.

The methods for ADR detection, evaluation, and monitoring should be strengthened from the grass-root level, especially in oncology. The role of pharmacovigilance program in monitoring the safety cancer chemotherapy should be evaluated for detection of newer and rarer ADRs. Improvement in spontaneous reporting of ADRs in oncology can only be achieved through sensitization and awareness lectures using audiovisual means not only to HCPs but also to residents, interns, and nurses as well. In addition, patient population should also be encouraged to report whenever they feel anything that in their opinion is not normal. Laboratory staff may also be vital in detecting any abnormality in laboratory tests consequent to drug exposure. Moreover, to strengthen ADR detection and reporting at grass-root level, the public at large may play an important role if they are well informed in their own language about proper use and safety of drugs through various means, i.e., TV, radio, print media, social media or public awareness lecture, etc. The motivation for voluntary reporting of ADRs for preventing the morbidity and mortality in this vulnerable population could be of immense importance.
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